Nykode Therapeutics – Grant of Share Options
Nykode Therapeutics ASA (NYKD) · publisert 10. oktober 2025 kl. 17:44 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Louise Stubbe | Chief Legal Officer | Annet Tildeling | 1 200 000 | 0 NOK | 10. oktober 2025 | NO0010714785 | Outside of trading venue |
Vedlegg
- Attachment Options 251010.pdf (application/pdf, originaldokument)
Meldingstekst
Oslo, Norway, October 10, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that 1,200,000 share options have been granted to an employee and primary insider under the company’s share option scheme. The share options will have a strike price of NOK 7.00 per share, vest equally over a four-year vesting period and expire in 2030.
Please see further details in attached document.